A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia
- Conditions
- cancerLeukemia10024324
- Registration Number
- NL-OMON45865
- Lead Sponsor
- Millennium Pharmaceuticals, Inc. (Takeda)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 6
1. Male or female patients 18 years or older.
2. Morphologically confirmed diagnosis of MDS, nonproliferative CMML
(ie, with WBC <20,000/µL), or low-blast AML based on 1 of the
following: French-American-British (FAB) Classifications:
- Refractory anemia with excess blasts (RAEB - defined as having 5% to 20% myeloblasts in the bone marrow).
- CMML with 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood.;OR;World Health Organization (WHO) Classifications:
- Refractory anemia with excess blasts-1 (RAEB-1 - defined as having 5% to 9% myeloblasts in the bone marrow).
- Refractory anemia with excess blasts-2 (RAEB-2 - defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood).
- Chronic Myelomonocytic Leukemia-2 (CMML-2 - defined as having 10% to 19% myeloblasts in the bone marrow and/or 5% to 19% blasts in the blood).
- Chronic Myelomonocytic Leukemia-1 (Although CMML-1 is defined as having <10% myeloblasts in the bone marrow and/or <5% blasts in the blood, these patients may enroll only if bone marrow blasts >=5%).
- WHO-defined AML with 20% to 30% myeloblasts in the bone marrow (defined in this protocol as Low-Blast AML) and < 30% myeloblasts in peripheral blood who are considered by investigator to be appropriate for azacitidine-based therapy.;3. For MDS and CMML patients, prognostic Risk Category, based on the Revised International Prognostic Scoring System (IPSS-R):
- Very high (>6 points),
- High (>4.5 - 6 points), or
- Intermediate (>3 - 4.5 points): a patient determined to be in the Intermediate Prognostic Risk Category is only allowable in the setting of >=5% bone marrow myeloblasts.
Patients with indeterminate cytogenetics findings at Screening should be assigned a cytogenetics prognostic variable of 2 points (ie, intermediate) for determining overall Prognostic Risk Category/Score
4. ECOG performance status of 0 to 2
5. Clinical laboratory values within the following parameters (repeat within 3 days before the first dose of study drug if laboratory values
used for randomization were obtained more than 3 days before the first dose of study drug):
- Albumin >2.7 g/dL.
- Total bilirubin - ALT and AST <2.5 × ULN.
- Creatinine clearance >50 mL/min
- Hemoglobin >8 g/dL. Patients may be transfused to achieve this value. Elevated indirect bilirubin due to post-transfusion hemolysis is allowed.
6. For CMML patients: WBC count <20,000/µL before administration of the first dose of study drug on Cycle 1 Day 1; patients must have been off hydroxyurea for at least 1 week prior to WBC count assessment.
7. Ability to undergo the study-required bone marrow sample collection procedures.
8. Suitable venous access for the study-required blood sampling (ie, including PK and biomarker sampling).
9. Female patients who:
- Are postmenopausal for at least 1 year before the Screening visit, or
- Are surgically sterile, or
- If they are of childbearing potential, agree to practice 1 highly effective methods and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, or
- Agree to
1. Previous treatment with decitabine or azacitidine or other hypomethylating agent.
2. Acute promyelocytic leukemia as diagnosed by morphologic examination of bone marrow, by fluorescent in situ hybridization or cytogenetics of peripheral blood or bone marrow, or by other accepted analysis.
3. Eligible for allogenic stem cell transplantation.
4. Patients with MDS, CMML, or low-blast AML, whose only site of disease is extramedullary, eg, the skin.
5. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures or could limit patient expected survival to less than 6 months.
6. Treatment with any anti-leukemic/anti-MDS therapies (eg, lenalidomide, cytarabine, anthracyclines, purine analogs) or with any investigational products within 14 days before the first dose of any study drug.
7. Known hypersensitivity to mannitol.
8. Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
9. Major surgery within 14 days before first dose or a scheduled surgery during study period; insertion of a venous access device (eg, catheter, port) is not considered major surgery.
10. Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
11. Life-threatening illness unrelated to cancer.
12. Prothrombin time (PT) or aPTT > 1.5 ULN or active uncontrolled coagulopathy or bleeding disorder.
13. Known human immunodeficiency virus (HIV) seropositive.
14. Known hepatitis B surface antigen seropositive, or known or suspected active hepatitis C infection. Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load.
15. Known hepatic cirrhosis or severe pre-existing hepatic impairment.
16. Known cardiopulmonary disease defined as unstable angina, clinically significant arrhythmia, congestive heart failure (New York Heart Association [NYHA] Class III or IV; see Section 15.3), and/or myocardial infarction within 6 months prior to first dose, or severe pulmonary hypertension. As an example, well-controlled atrial fibrillation would not be an exclusion whereas uncontrolled atrial fibrillation would be an exclusion.
17. Treatment with strong CYP3A inhibitors or inducers within 14 days before the first dose of pevonedistat.
18. Systemic antineoplastic therapy or radiotherapy for other conditions within 12 months before the first dose of any study drug, except for hydroxyurea.
19. Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
study drug.
20. Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).
21. Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>EFS; for patients with HR MDS or CMML, an event is defined as death or<br /><br>transformation to AML; for patients with low-blast AML, an event is defined as<br /><br>death or disease progression (see Section 7.4.21). </p><br>
- Secondary Outcome Measures
Name Time Method